Detalhe da pesquisa
1.
Analysis of Genes Associated With Monogenic Primary Immunodeficiency Identifies Rare Variants in XIAP in Patients With Crohn's Disease.
Gastroenterology
; 154(8): 2165-2177, 2018 06.
Artigo
em Inglês
| MEDLINE | ID: mdl-29501442
2.
Predictive models assessing the response to ustekinumab highlight the value of therapeutic drug monitoring in Crohn's disease.
Dig Liver Dis
; 55(3): 366-372, 2023 Mar.
Artigo
em Inglês
| MEDLINE | ID: mdl-35977875
3.
Crohn's disease-related 'gastrocnemius myalgia syndrome' successfully treated with infliximab: A case report.
World J Gastroenterol
; 28(7): 755-762, 2022 Feb 21.
Artigo
em Inglês
| MEDLINE | ID: mdl-35317272
4.
Introduction of Subcutaneous Infliximab CT-P13 and Vedolizumab in Clinical Practice: A Multi-Stakeholder Position Statement Highlighting the Need for Post-Marketing Studies.
J Crohns Colitis
; 16(7): 1059-1069, 2022 Aug 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-35078228
5.
Collecting New Peak and Intermediate Infliximab Levels to Predict Remission in Inflammatory Bowel Diseases.
Inflamm Bowel Dis
; 28(2): 208-217, 2022 02 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-33783494
6.
New approach to determine the healthy immune variations by combining clustering methods.
Sci Rep
; 11(1): 8917, 2021 04 26.
Artigo
em Inglês
| MEDLINE | ID: mdl-33903641
7.
Effectiveness of Third-Class Biologic Treatment in Crohn's Disease: A Multi-Center Retrospective Cohort Study.
J Clin Med
; 10(13)2021 Jun 29.
Artigo
em Inglês
| MEDLINE | ID: mdl-34209880
8.
Switching biologics used in inflammatory bowel diseases: how to deal with in practice?
Curr Opin Pharmacol
; 55: 82-89, 2020 12.
Artigo
em Inglês
| MEDLINE | ID: mdl-33166871
9.
New insights in acetaminophen toxicity: HMGB1 contributes by itself to amplify hepatocyte necrosis in vitro through the TLR4-TRIF-RIPK3 axis.
Sci Rep
; 10(1): 5557, 2020 03 27.
Artigo
em Inglês
| MEDLINE | ID: mdl-32221312
10.
Effectiveness of ustekinumab dose escalation in Crohn's disease patients with insufficient response to standard-dose subcutaneous maintenance therapy.
Aliment Pharmacol Ther
; 52(1): 135-142, 2020 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-32412134
11.
Impact of first-line infliximab on the pharmacokinetics of second-line vedolizumab in inflammatory bowel diseases.
United European Gastroenterol J
; 7(6): 750-758, 2019 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-31316779
12.
Variability of Faecal Calprotectin in Inflammatory Bowel Disease Patients: An Observational Case-control Study.
J Crohns Colitis
; 13(11): 1372-1379, 2019 Oct 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-30944925
13.
Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance.
Eur J Gastroenterol Hepatol
; 31(4): 478-485, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30672828
14.
Long-term Clinical Effectiveness of Ustekinumab in Patients with Crohn's Disease Who Failed Biologic Therapies: A National Cohort Study.
J Crohns Colitis
; 13(11): 1401-1409, 2019 Oct 28.
Artigo
em Inglês
| MEDLINE | ID: mdl-30989232
15.
Does colectomy in UC patients impact on the PSC onset?: A national registry brings new insights.
United European Gastroenterol J
; 11(4): 319-320, 2023 05.
Artigo
em Inglês
| MEDLINE | ID: mdl-37118868
16.
Viewpoint: Toward the Genetic Architecture of Disease Severity in Inflammatory Bowel Diseases.
Inflamm Bowel Dis
; 24(7): 1428-1439, 2018 06 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-29788122
17.
Infliximab Trough Levels at Induction to Predict Treatment Failure During Maintenance.
Inflamm Bowel Dis
; 23(8): 1371-1381, 2017 08.
Artigo
em Inglês
| MEDLINE | ID: mdl-28498153